Nasdaq Rani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq rani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Rani Today - Breaking & Trending Today

Rani Therapeutics Holdings, Inc. Forecasted to Earn FY2024 Earnings of ($1.00) Per Share (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Stock analysts at Zacks Small Cap increased their FY2024 earnings per share estimates for Rani Therapeutics in a research note issued to investors on Thursday, March 21st. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings per share of ($1.00) for […] ....

United States , Rani Therapeutics Company Profile , Tower Research Capital , Jpmorgan Chase Co , Rani Therapeutics Holdings Inc , America Corp , Rani Therapeutics Holdings , Free Report , Zacks Small Cap , Rani Therapeutics , Small Cap , Rani Therapeutic , Research Capital , Street Group , Get Free Report , Therapeutics Holdings , Rani Therapeutics Daily , Nasdaq Rani , Earnings Estimates ,

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) to Post FY2024 Earnings of ($1.00) Per Share, Zacks Small Cap Forecasts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Zacks Small Cap raised their FY2024 earnings per share (EPS) estimates for shares of Rani Therapeutics in a research note issued on Thursday, March 21st. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of ($1.00) per share for the year, […] ....

Rani Therapeutics Holdings Inc , Millennium Management , Goldman Sachs Group Inc , Vanguard Group Inc , Blackrock Inc , Rani Therapeutics Holdings , Free Report , Zacks Small Cap , Rani Therapeutics , Small Cap , Rani Therapeutic , Therapeutics Stock Down , Street Corp , Sachs Group , Get Free Report , Therapeutics Holdings , Rani Therapeutics Daily , Nasdaq Rani , Earnings Estimates ,

Wedbush Comments on Rani Therapeutics Holdings, Inc.'s FY2027 Earnings (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Equities researchers at Wedbush decreased their FY2027 earnings per share (EPS) estimates for Rani Therapeutics in a research note issued to investors on Tuesday, February 6th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($1.78) per share for the year, down […] ....

Cortes Isidoro Alfonso Quiroga , Talat Imran , Millennium Management , Geode Capital Management , Vanguard Group Inc , Securities Exchange Commission , Blackrock Inc , Rani Therapeutics Holdings Inc , Stifel Financial Corp , Rani Therapeutics Holdings , Free Report , Rani Therapeutics , Rani Therapeutic , Get Free Report , Exchange Commission , Financial Corp , Capital Management , Therapeutics Holdings , Rani Therapeutics Daily , Nasdaq Rani , Earnings Estimates ,

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) CEO Talat Imran Buys 5,000 Shares

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) CEO Talat Imran acquired 5,000 shares of the stock in a transaction on Monday, December 4th. The stock was purchased at an average cost of $2.57 per share, with a total value of $12,850.00. Following the transaction, the chief executive officer now directly owns 474,455 shares […] ....

United States , Talat Imran , Tower Research Capital , Jpmorgan Chase Co , Icon Wealth Partners , Rani Therapeutics Holdings Inc , America Corp , Rani Therapeutics Company Profile , Securities Exchange Commission , Rani Therapeutics Holdings , Get Free Report , Exchange Commission , Rani Therapeutics , Therapeutics Stock Down , Therapeutics Holdings , Research Capital , Wealth Partners , Jane Street Group , Rani Therapeutics Daily , Nasdaq Rani , Insider Trading , Nsider Trades ,

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) CEO Buys $41,000.00 in Stock

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) CEO Talat Imran purchased 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $2.05 per share, for a total transaction of $41,000.00. Following the acquisition, the chief executive officer now directly […] ....

United States , Talat Imran , Blackrock Inc , Goldman Sachs Group Inc , Rani Therapeutics Holdings Inc , Millennium Management , Rani Therapeutics Company Profile , Vanguard Group Inc , Rani Therapeutics Holdings , Get Free Report , Rani Therapeutics , Street Corp , Sachs Group , Therapeutics Holdings , Rani Therapeutics Daily , Nasdaq Rani , Insider Trading , Nsider Trades ,